DexCom has reported strong financial performance, exceeding expectations for the first quarter of 2026 and beating 2025 revenue targets. Despite this, the company's stock price has dropped. Some outlets are advising investors to hold or retain their DexCom stock, while others suggest it may be a good time to add to their portfolio.